Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia : Combined Subgroup Analyses of the RECORD-1 and REACT Trials by Bono, Petri et al.
406 -Original StudyOutcomes in Patients With Metastatic Renal Cell
Carcinoma Who Develop Everolimus-Related
Hyperglycemia and Hypercholesterolemia:
Combined Subgroup Analyses of the RECORD-1
and REACT Trials
Petri Bono,1 Stephane Oudard,2 Istvan Bodrogi,3 Thomas E. Hutson,4
Bernard Escudier,5 Jean-Pascal Machiels,6 John A. Thompson,7 Robert A. Figlin,8
Alain Ravaud,9 Mert Basaran,10 Camillo Porta,11 Sergio Bracarda,12
Thomas Brechenmacher,13 Chinjune Lin,14 Maurizio Voi,14 Viktor Grunwald,15
Robert J. Motzer16
Abstract
In this study we examined the outcome of metastatic renal cell cancer patients with everolimus treatment-
related hyperglycemia and hypercholesterolemia. All patients were treated in 2 large, international prospec-
tive trials, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) and REACT (RAD001
Expanded Access Clinical Trial in RCC). Patients who experienced these events might have experienced an
improved response to everolimus.
Background: Hyperglycemiaandhypercholesterolemia areclasseffectsofmammalian target of rapamycin inhibitors. The
purpose of this study was to characterize safety and efﬁcacy of patients with metastatic renal cell carcinoma (mRCC)
treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) and REACT (RAD001
Expanded Access Clinical Trial in RCC) who developed these events. Patients and Methods: Adults with vascular
endothelial growth factorerefractory mRCC received everolimus 10 mg/d in the randomized RECORD-1 (n ¼ 277) and
open-label REACT (n¼ 1367) studies. Outcomes included safety, treatment duration, overall response, and progression-
free survival for patients who developed hypercholesterolemia or hyperglycemia. Results: In RECORD-1, 12% (33 of
277) and 20% (55 of 277) of patients developed any grade hyperglycemia or hypercholesterolemia, respectively, with
only 6% (78 of 1367) and 1% (14 of 1367) of the same events, respectively, in REACT. Median everolimus treatment
duration was similar for patients with hyperglycemia or hypercholesterolemia (RECORD-1, 6.2 and 6.2 months,
respectively; REACT, 4.4 and 4.5 months, respectively), but longer than the overall populations (RECORD-1, 4.6 months;
REACT, 3.2 months). In RECORD-1/REACT, 82%/68% of patients with hyperglycemia and 75%/71% of patients with
hypercholesterolemia achieved partial response or stable disease. The incidence of clinically notable Grade 3 or 41Comprehensive Cancer Center, Helsinki University Hospital and University of Hel-
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adverse events, other than anemia and lymphopenia, appeared to be similar across trials and subgroups. Although there
was a trend for improved progression-free survival with development of hyperglycemia or hypercholesterolemia, the
association was not statistically signiﬁcant. Conclusion: Hyperglycemia and hypercholesterolemia were observed in low
numbers of patients, and although these events might be associated with improved response to everolimus, the
differences were not signiﬁcant. These ﬁndings should be validated with prospective biomarker studies.
Clinical Genitourinary Cancer, Vol. 14, No. 5, 406-14 ª 2016 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Everolimus, a mammalian target of rapamycin (mTOR) inhibi-
tor, has shown efﬁcacy and safety in the treatment of patients with
metastatic renal cell carcinoma (mRCC). In the phase III
RECORD-1 (REnal Cell cancer treatment with Oral RAD001
given Daily; Clinicaltrials.gov: NCT00410124) study, vascular
endothelial growth factor (VEGF)-refractory patients treated with
everolimus versus placebo had longer median progression-free sur-
vival (PFS; 4.9 months vs. 1.9 months; hazard ratio [HR], 0.33;
P < .001).1 Everolimus was generally well tolerated and there was a
low rate of Grade 3 or 4 adverse events (AEs). REACT (RAD001
Expanded Access Clinical Trial in RCC; ClinicalTrials.gov:
NCT00655252) was initiated to provide everolimus to patients
before it became commercially available and to further assess safety
and efﬁcacy of everolimus in VEGF receptor-tyrosine kinase
inhibitorerefractory patients with mRCC.2 Results of REACT were
consistent with those from RECORD-1.
Inhibition of the mTOR pathway provides clinical beneﬁt to pa-
tients with mRCC, but the mechanism leads to certain class effects,
including hyperglycemia and hyperlipidaemia.3 In this analysis, we
evaluated the potential association of these AEs with outcomes in
patients treated with everolimus in RECORD-1 and REACT.
Patients and Methods
Study Design
Study designs for RECORD-11 and REACT2 have been previ-
ously reported. Both studies included VEGF-refractory patients
with mRCC and a Karnofsky performance status (KPS) 70% and
excluded patients with uncontrolled diabetes as deﬁned according to
fasting serum glucose >1.5 times the upper limit of normal (ULN)
in RECORD-1 or >2 times the ULN in REACT. In RECORD-1,
patients received everolimus 10 mg once daily (n ¼ 277) or placebo
(n ¼ 139), both with best supportive care.1 In REACT, patients
(n ¼ 1367) received everolimus 10 mg once daily until disease
progression, unacceptable toxicity, death, discontinuation (patient
or physician discretion), commercial availability, or June 15, 2010
(whichever came ﬁrst).2 In both studies, dose reduction to 5 mg
daily was permitted if unacceptable toxicity occurred.
Assessments
Safety was assessed at baseline, then monthly for up to 28 days after
the last dose of study drug and included physical examination, assess-
ment of KPS, electrocardiography, and hematology, chemistry, lipid,
and coagulation proﬁles. AEs and laboratory abnormalities were graded
according to the National Cancer Institute’s Common TerminologyCriteria for AEs (version 3.0). In RECORD-1, all AEs were monitored
and recorded. Fasting glucose and total cholesterol levels weremeasured
at screening and on day 1 of each treatment cycle and at study
discontinuation. If an increase in serum glucose or cholesterol required
dose modiﬁcation or interruption, testing was repeated until levels
returned to baseline. In REACT, data on all Grade 3 and 4 AEs were
collected; data on Grades 1 and 2 AEs were collected only if their
occurrence resulted in a change in study drug administration (dose
modiﬁcation/interruption or treatment discontinuation).
In RECORD-1, tumor measurements were assessed (Response
Evaluation Criteria In Solid Tumors [RECIST] version 1.0) at
screening, every 8 weeks thereafter, and at study discontinuation.
Assessments were done by a local investigator and central review. In
REACT, best overall tumor response was assessed (RECIST version
1.0) at baseline, every 3 months for the ﬁrst year, every 6 months
thereafter, and at study discontinuation. Assessment was done by
local investigator review.
Patients included in this subgroup analysis developed hyperglyce-
mia or hypercholesterolemia during everolimus treatment. In
RECORD-1, patients who developed any grade hyperglycemia or
hypercholesterolemia were included. In REACT, patients who
developed Grades 3 or 4 hyperglycemia or hypercholesterolemia and
patients who developed Grades 1 or 2 hyperglycemia or hypercho-
lesterolemia that resulted in a change in study drug administration
were included. Descriptive statistics were used. Logistic regression
analysis was performed to assess the effect of elevated baseline glucose
or cholesterol levels on best overall tumor response. A landmark
analysis of PFS according to central assessment was performed for
patients treated for 8 weeks and according to occurrence of any
grade hyperglycemia or hypercholesterolemia within the ﬁrst 8 weeks
of treatment. The landmark analysis was used to correct bias inherent
to the confounding effect of duration of exposure and the 8-week
cutoff was chosen because it corresponded to the ﬁrst scheduled tu-
mor assessment, plus a high number of hyperglycemia or hypercho-
lesterolemia events occurred by this time. PFS estimates were
obtained using the KaplaneMeier method. HRs were calculated
using the Cox proportional hazards model. Statistical analyses were
performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Patients
In RECORD-1, 12% of patients (33 of 277) developed hyper-
glycemia and 20% of patients (55 of 277) developed hypercholes-
terolemia; there was a signiﬁcant correlation between development
of the 2 events (c2 test, P ¼ .0005). Among the 33 cases ofClinical Genitourinary Cancer October 2016 - 407
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408 -hyperglycemia, 7 were Grade 1 (21%), 9 were Grade 2 (27%), and
17 were Grade 3 (52%). Among the 55 cases of hypercholester-
olemia, 30 were Grade 1 (55%), 16 were Grade 2 (29%), and 9
were Grade 3 (16%). In REACT, 6% of patients (78 of 1367)
developed hyperglycemia and 1% of patients (14 of 1367) devel-
oped hypercholesterolemia. Among the 78 cases of hyperglycemia, 3
were Grade 1 or 2 (4%), 67 were Grade 3 (86%), and 8 were Grade
4 (10%), and among the 14 cases of hypercholesterolemia, 2 were
Grade 1 or 2 (14%), 9 were Grade 3 (64%), and 3 were Grade 4
(21%).
Baseline characteristics (Table 1) were similar between patients who
developed either AE and all everolimus-treated patients. One notable
exception was that in both trials, a greater proportion of Asian patients
appeared more likely to develop hyperglycemia. Although representing
6%of the RECORD-1 population and 8%of the REACTpopulation,
Asian patients represented 12% and 17% of patients with hypergly-
cemia from RECORD-1 or REACT, respectively.
Among RECORD-1 patients who developed hyperglycemia,
median baseline glucose was 6.3 mmol/L (range, 5-11) and the
median increase in serum glucose was 2.0 mmol/L at end of
treatment. Among RECORD-1 patients who developed hyper-
cholesterolemia, median baseline cholesterol was 4.9 mmol/L
(range, 3-9) and the median increase in serum cholesterol was
1.2 mmol/L at end of treatment. Increases over time in glucose
levels of patients with hyperglycemia and in cholesterol levels of
patients with hypercholesterolemia are shown in Figure 1. In
RECORD-1, 63% of patients with hyperglycemia were taking
medication to control their diabetes at the start of the study (met-
formin, 18%; sulfonamide urea, 15%; and insulin, 30%). In
addition, 15% of patients with hyperglycemia were taking lipid-
lowering medication (hydroxymethyl gluctaryl coenzyme A
[HMG CoA] reductase inhibitors) at the start of the study. Among
patients with hypercholesterolemia, 22% (12 of 55) were taking
lipid-lowering medication (HMG CoA reductase inhibitors) and
22% (12 of 55) were taking medication to control diabetes (met-
formin, 4%; sulfonamide urea, 4%; and insulin, 14%) at the start of
the study. REACT patients with hyperglycemia were taking met-
formin (31%; 24 of 78), sulfonamide urea (27%; 21 of 78), and/or
insulin (54%; 42 of 78) for glucose control at the start of the study.
In addition, 44% of patients with hyperglycemia were taking lipid-
lowering medication at the start of the study (HMG CoA reductase
inhibitors alone or in combination with other lipid-lowering drugs).
Among patients with hypercholesterolemia, 29% (4 of 14) were
taking HMG CoA reductase inhibitors alone or in combination
with other lipid modiﬁers at the start of the study (1 patient was
taking sulfonamide urea).
Dose Modiﬁcations and Treatment Duration
In RECORD-1, 4.3 weeks was the median time to development
of hyperglycemia (n ¼ 33; 95% conﬁdence interval [CI], 4.0-8.0)
or hypercholesterolemia (n ¼ 55; 95% CI, 4.1-8.0). Among
RECORD-1 patients who developed hyperglycemia, 6% (2 of 33)
required a dose adjustment or study drug interruption and 61% (20
of 33) received concomitant medications to manage the event. No
patients discontinued treatment because of hyperglycemia. Among
RECORD-1 patients who developed hypercholesterolemia, 2% (1
of 55) required a dose adjustment or study drug interruption andClinical Genitourinary Cancer October 201631% (17 of 55) received concomitant medications to manage the
event. No patients discontinued treatment because of
hypercholesterolemia.
Among REACT patients who developed hyperglycemia, 36%
(28 of 78) required a dose adjustment (24 [31%] Grade 3 and 3
[4%] Grade 4) and 68% (53 of 78) received concomitant medi-
cations (43 [55%] Grade 3 and 7 [9%] Grade 4). Among patients
who developed hypercholesterolemia, 29% (4 of 14) required a dose
adjustment (1 [7%] Grade 3 and 1 [7%] Grade 4), and 43% (6 of
14) received concomitant medications (3 [21%] Grade 3 and 2
[14%] Grade 4).
In REACT, 4% of patients discontinued because of hypergly-
cemia (0 Grade 3 and 2 [3%] Grade 4) and 7% of patients dis-
continued because of hypercholesterolemia (1 [7%] Grade 3).
RECORD-1 and REACT patients who developed hyperglycemia
or hypercholesterolemia had longer median treatment duration than
the total study populations. In RECORD-1, median treatment
duration was 6.2 months each for patients with either AE and 4.6
months for all everolimus-treated patients. In REACT, median
treatment duration was 4.4 months for patients with hyperglycemia,
4.5 months for patients with hypercholesterolemia, and 3.2 months
for the total population.
In RECORD-1 and REACT, a greater percentage of patients
with either AE than of patients in the total study populations had a
treatment duration of 8 months (Figure 2). In RECORD-1, 39%
of patients with hyperglycemia, 38% of patients with hypercholes-
terolemia, and 26% of the everolimus-treated population were
treated for 8 months. In REACT, 24% of patients with hyper-
glycemia, 21% of patients with hypercholesterolemia, and 19% of
the total population were treated for >8 months.
Efﬁcacy
Similar percentages of patients in RECORD-1 and REACT
who developed either AE achieved partial response (PR) or stable
disease (SD) from treatment with everolimus (Table 2). In
RECORD-1 and REACT, 82% and 68% of patients with hy-
perglycemia, respectively, achieved PR or SD. Similarly, in
RECORD-1 and REACT, 75% and 71% of patients with hy-
percholesterolemia, respectively, achieved PR or SD. In all
RECORD-1 and REACT patients, 69% and 54%, respectively,
achieved PR or SD. In RECORD-1, patients with elevated
baseline glucose levels had a greater tumor response rate than
patients without elevated baseline glucose level (odds ratio, 1.33;
95% CI, 1.06-1.67).
In RECORD-1, there was no signiﬁcant effect of elevated
baseline glucose level on PFS; however, patients with elevated
baseline cholesterol level had a greater chance of experiencing
shorter PFS than patients without elevated baseline cholesterol level
(HR, 0.83; 95% CI, 0.75-0.93). In the RECORD-1 landmark
analysis at week 8, median PFS was 5.9 months (95% CI, 4.0-not
estimable [NE]) and 5.4 months (95% CI, 4.3-5.6) for those who
did and did not develop hyperglycemia, respectively (HR, 0.70;
95% CI, 0.37-1.30) and 5.9 months (95% CI, 4.0-NE) and 5.1
months (95% CI, 4.3-5.6) for those who did and did not develop
hypercholesterolemia, respectively (HR, 0.76; 95% CI, 0.45-1.27;
Table 3). At the 8-week landmark, 87% of patients (240 of 277)
had been treated with everolimus for 8 weeks. Although there was
Table 1 Baseline Characteristics of All Patients in the Everolimus Arm of RECORD-1, All Patients in REACT, and the Subgroups of Everolimus-Treated Patients in Each Trial Who Developed
Hyperglycemia or Hypercholesterolemia
Characteristic
RECORD-1 Everolimus Arm REACT
All Patients
(n [ 277)
Patients With
Hyperglycemia
(n [ 33)
Patients With
Hypercholesterolemia
(n [ 55)
All Patients
(n [ 1367)
Patients With
Hyperglycemia
(n [ 78)
Patients With
Hypercholesterolemia
(n [ 14)
Median Age, Years 61 62 61 63 63 62
Sex, n (%)
Male 216 (78) 26 (798) 44 (80) 989 (72) 54 (69) 9 (64)
Female 61 (22) 7 (21) 11 (20) 378 (287) 24 (31) 5 (36)
Race, n (%)
White 246 (89) 28 (85) 51 (93) 1220 (89) 64 (82) 11 (79)
Asian 16 (6) 4 (12) 3 (6) 114 (8) 13 (17) 1 (7)
Other 11 (4) 1 (3) 1 (2) 33 (2) 1 (1) 2 (14)
Missing 4 (1) 0 0 0 0 0
Tumor Histology, n (%)
Clear cell adenocarcinoma 266 (96) 32 (97) 53 (96) 1283 (94) 73 (94) 14 (100)
Other 11 (4) 1 (3) 2 (4) 75 (6) 5 (6) 0
Missing 0 0 0 9 (1) 0 0
Histological Grade, n (%)
Well differentiated 22 (8) 1 (3) 6 (11) 76 (6) 3 (4) 0
Moderately differentiated 57 (21) 10 (30) 14 (26) 369 (27) 18 (23) 5 (36)
Poorly differentiated 84 (30) 10 (30) 17 (31) 351 (26) 21 (27) 3 (21)
Undifferentiated 17 (6) 3 (9) 1 (2) 106 (8) 5 (6) 1 (7)
Unknown 97 (35) 9 (27) 17 (31) 465 (34) 31 (40) 5 (36)
Median Cholesterol, mmol/L (range)a 4.6 (2-10) 4.9 (3-8) 4.9 (3-9) e e e
Median Glucose, mmol/L (range)b 5.5 (3-19) 6.3 (5-11) 5.4 (4-11) e e e
Abbreviations: REACT ¼ RAD001 Expanded Access Clinical Trial in RCC; RECORD-1 ¼ REnal Cell cancer treatment with Oral RAD001 given Daily.
aNormal level of total cholesterol is < 5.2 mmol/L (<201 mg/dL).
bNormal range of glucose is 4.5-7.0 mmol/L (81-126 mg/dL).
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Figure 1 Median Changes From Baseline Over Time in (A) Glucose and (B) Cholesterol Levels for Patients Treated With Everolimus in
RECORD-1 (REnal Cell Cancer Treatment With Oral RAD001 Given Daily)
Abbreviation: EOT ¼ end of treatment.
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410 -a trend for an association between development of these AEs and
longer PFS, it was not statistically signiﬁcant. Of note, the same
analysis was conducted without adjustment (no landmark; Table 3).Clinical Genitourinary Cancer October 2016Although results of this unadjusted analysis were statistically sig-
niﬁcant, they should be interpreted with caution because of the
confounding effect of duration of exposure.
Figure 2 Everolimus Treatment Duration in (A) RECORD-1 (REnal Cell Cancer Treatment With Oral RAD001 Given Daily) and (B) REACT
(RAD001 Expanded Access Clinical Trial in RCC) for the Overall Populations and for Patients With Hyperglycemia or
Hypercholesterolemia.
aSafety Population (n ¼ 274); 3 Patients Who Were Randomized Were Excluded From the Safety Population
Petri Bono et alSafety
In RECORD-1 and REACT, the incidence of patients who
experienced Grade 3 or 4 anemia was higher for patients with
hyperglycemia and lower for patients with hypercholesterolemia,
compared with patients in the total study populations (Table 4).
In RECORD-1, the incidence of patients who experienced
Grade 3 or 4 lymphopenia was higher for patients withhypercholesterolemia and lower for patients with hyperglycemia,
compared with patients in the total study population. In
REACT, more patients with hyperglycemia or hypercholester-
olemia than patients in the overall population experienced Grade
3 or 4 lymphopenia. The incidence of other clinically notable
Grade 3 or 4 AEs appeared to be similar across trials and sub-
groups (Table 4).Clinical Genitourinary Cancer October 2016 - 411
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The correlation of speciﬁc AEs with clinical efﬁcacy of targeted
therapies in mRCC has been controversial. Hypertension is a class
effect of anti-VEGF therapy.4-7 Results of some studies have
shown that treatment-induced hypertension was associated with
improved outcomes in patients treated with axitinib,8-11 bev-
acizumab,12 sorafenib,13 and sunitinib.12,14,15 However, results of
another study showed a weak correlation between axitinib steady-
state exposure and change in diastolic blood pressure from base-
line.16 Hyperglycemia and hyperlipidaemia are class effects of
mTOR inhibition.3 Results of a retrospective study of patients
from the temsirolimus registration trial showed that temsirolimus’
effect on cholesterol, but not on glucose, predicted its effect on
survival; longer survival with temsirolimus was observed in pa-
tients with larger increases in cholesterol.17 We found that
everolimus-treated patients from RECORD-1 and REACT who
developed hyperglycemia or hypercholesterolemia had longer
median treatment durations than patients in the total populations.
A higher percentage of patients who developed hyperglycemia or
hypercholesterolemia than in the total RECORD-1 and REACT
populations achieved PR or SD. In this analysis of RECORD-1,
elevated baseline glucose level was associated with an increased
rate of tumor response. Although the 8-week landmark analysis
showed a trend for improved PFS and development of hypergly-
cemia or hypercholesterolemia, the associations were not statisti-
cally signiﬁcant. Results of the landmark analysis should be
interpreted with caution because of low patient numbers and low
numbers of PFS events.
In RECORD-1, abnormal serum glucose values were observed in
57% of patients who received everolimus and 25% of patients who
received placebo; the incidence of hyperglycemia was 8%
and <1%, respectively.1,18 Most cases of hyperglycemia occurred in
patients with abnormal fasting glucose levels before treatment; 1
new case of diabetes mellitus was reported during the trial.18
Among patients who developed hyperglycemia in RECORD-1
and REACT, 52% and 96%, respectively, experienced it as a
Grade 3 or 4 event. Among patients who developed hypercholes-
terolemia in RECORD-1 and REACT, 16% and 86%, respec-
tively, experienced it as a Grade 3 or 4 event. In REACT, data on
Grades 1 and 2 AEs were captured only if they resulted in a change
in study drug administration (ie, dose modiﬁcation, temporary
interruption, or treatment discontinuation). This might explain the
higher percentage of patients in the REACT hyperglycemia and
hypercholesterolemia subgroups who experienced Grade 3 or 4
events compared with the corresponding groups from RECORD-1.
It might also explain the smaller sizes of the REACT subgroups
relative to the total study population than the corresponding sub-
groups from RECORD-1. Although Asian patients treated with
everolimus in both studies appeared more likely to develop
hyperglycemia, patients from European countries who participated
in REACT developed the event at rates similar to the overall
population.19 Management guideline goals for patients with cancer
who develop mTOR inhibitor-associated hyperlipidaemia (eleva-
tions in total cholesterol, low-density lipoprotein, and triglyceride
levels) or hyperglycemia are to decrease short-term morbidity
associated with these AEs.20 All patients who receive mTOR
Table 3 RECORD-1: Analysis of Progression-Free Survival (Central Review) and Occurrence of Hyperglycemia or
Hypercholesterolemia During the Entire Study (No Landmark) and Within the First 8 Weeks of Treatment (Landmark)
No Landmark 8 Weeks
Patients Treated for At Least 8 Weeks, n/Total n (%) 277/277 (100) 240/277 (87)
Hyperglycemia/No Hyperglycemia
Patients, n/n 33/244 21/219
PFS events, n/n 15/140 11/123
Median PFS (95% CI), months 7.3 (4.0-NE)/4.5 (3.8-5.5) 5.9 (4.0-NE)/5.4 (4.3-5.6)
HR (95% CI) 0.50 (0.29-0.85) 0.70 (0.37-1.30)
Hypercholesterolemia/No Hypercholesterolemia
Patients, n/n 55/222 35/205
PFS events, n/n 28/127 17/117
Median PFS (95% CI), months 7.3 (5.2-11.9)/4.3 (3.7-5.4) 5.9 (4.0-NE)/5.1 (4.3-5.6)
HR (95% CI) 0.61 (0.40-0.92) 0.76 (0.45-1.27)
Abbreviations: HR ¼ hazard ratio; NE ¼ not estimable; PFS ¼ progression-free survival; RECORD-1 ¼ REnal Cell cancer treatment with Oral RAD001 given Daily.
Petri Bono et alinhibitor therapy should be screened and regularly monitored for
hyperlipidemia and hyperglycemia.
Conclusion
These results suggest that development of hyperglycemia and
hypercholesterolemia occur in low numbers of patients and do not
lead to everolimus discontinuation. Most patients who developed
these AEs continued therapy for a longer duration than patients in
the overall population. Patients who experience these events might
also experience an improved response to everolimus. There was aTable 4 Combined Grades 3 and 4 Clinically Notable Adverse Events
or Hypercholesterolemiaa
Adverse Event
All Patients
(n [ 274)b
Patie
Hyper
(n
Anemia 28 (10)
Hyperglycemia 17 (6) 1
Lymphopenia 12 (4)
Stomatitis 12 (4)
Hypercholesterolemia 9 (3)
Pneumonitis 7 (3)
R
All Patients
(n [ 1364)
Patie
Hype
(n
Anemia 183 (13) 2
Hyperglycemia 75 (6) 7
Stomatitis 74 (5)
Pneumonitis 37 (3)
Hypercholesterolemia 12 (<1)
Lymphopenia 12 (<1)
Data are presented as n (%).
Abbreviations: REACT ¼ RAD001 Expanded Access Clinical Trial in RCC; RECORD-1 ¼ REnal Cell
aClinically notable adverse events with a combined Grade 3/4 incidence of >2% in either the total
bSafety population (n ¼ 274); 3 patients who were randomized were excluded from the safety poptrend for an association between development of hyperglycemia and
hypercholesterolemia and longer PFS, but the differences were not
statistically signiﬁcant.
Clinical Practice Points
 Hyperglycemia and hypercholesterolemia are class effects of
mTOR inhibitors such as everolimus.
 In this analysis, we evaluated the potential association of these
AEs with outcomes in patients treated with everolimus in
RECORD-1 and REACT.in RECORD-1 and REACT Patients Who Developed Hyperglycemia
RECORD-1 Everolimus Arm
nts With
glycemia
[ 33)
Patients With
Hypercholesterolemia
(n [ 55)
Patients With
Hyperglycemia and
Hypercholesterolemia
(n [ 15)
5 (15) 2 (4) 1 (7)
7 (52) 10 (18) 10 (67)
1 (3) 5 (9) 1 (7)
1 (3) 3 (6) 0
3 (9) 9 (16) 4 (27)
0 0 0
EACT
nts With
rglycemia
[ 78)
Patients With
Hypercholesterolemia
(n [ 14)
1 (27) 1 (7)
5 (96) 0
7 (9) 0
3 (4) 0
0 12 (86)
2 (3) 1 (7)
cancer treatment with Oral RAD001 given Daily.
RECORD-1 population or the total REACT population are shown.
ulation.
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414 - Hyperglycemia and hypercholesterolemia were observed in low
numbers of patients, and although these events might be asso-
ciated with improved response to everolimus, the differences
were not statistically signiﬁcant.
 These ﬁndings should be validated with prospective biomarker
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